[A comparative study of serum sFas in patients with hepatocellular cancer and chronic hepatitis].
To study the effects of sFas in hepatocellular cancer (HCC) and chronic hepatitis (CH). The serum sFas was detected in 18 patients with HCC, 12 patients with CH and 6 cases of normal control by ELISA. The serum sFas in HCC was obviously increased and had significant difference with the patients of CH and normal control (P < 0.01). The serum sFas had positive correlation with the serum TBIL(P < 0.01), but negative correlation with the ALB, PTA and the ratio of ALT/AST(P < 0.01). sFas may resist the occurrence of HCC apoptosis. In CH, sFas has correlation with the severity of CH. The role of sFas in viral hepatitis is uncertain.